A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Clinical Trial ID NCT00000884

PubWeight™ 1.13‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00000884

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009 1.13
Next 100